Estrella Immunopharma (ESLA) Competitors $1.31 -0.01 (-0.76%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$1.28 -0.03 (-2.29%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. MIST, IPHA, ACTU, ENTA, TVGN, NVCT, GLSI, NLTX, BTMD, and CLYMShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Milestone Pharmaceuticals (MIST), Innate Pharma (IPHA), Actuate Therapeutics (ACTU), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Nuvectis Pharma (NVCT), Greenwich LifeSciences (GLSI), Neoleukin Therapeutics (NLTX), biote (BTMD), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Milestone Pharmaceuticals Innate Pharma Actuate Therapeutics Enanta Pharmaceuticals Tevogen Bio Nuvectis Pharma Greenwich LifeSciences Neoleukin Therapeutics biote Climb Bio Estrella Immunopharma (NASDAQ:ESLA) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Does the media favor ESLA or MIST? In the previous week, Estrella Immunopharma had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Estrella Immunopharma and 0 mentions for Milestone Pharmaceuticals. Estrella Immunopharma's average media sentiment score of 0.50 beat Milestone Pharmaceuticals' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Positive Milestone Pharmaceuticals Neutral Is ESLA or MIST more profitable? Estrella Immunopharma's return on equity of -1,132.38% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -358.54% Milestone Pharmaceuticals N/A -1,672.29%-83.09% Do insiders & institutionals hold more shares of ESLA or MIST? 0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, ESLA or MIST? Estrella Immunopharma has higher earnings, but lower revenue than Milestone Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/A-$0.26-5.04Milestone Pharmaceuticals$1M179.33-$41.52M-$0.84-2.51 Which has more risk and volatility, ESLA or MIST? Estrella Immunopharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Do analysts rate ESLA or MIST? Estrella Immunopharma currently has a consensus target price of $16.00, indicating a potential upside of 1,121.37%. Milestone Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 113.27%. Given Estrella Immunopharma's higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Milestone Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Milestone Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryMilestone Pharmaceuticals beats Estrella Immunopharma on 7 of the 13 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.56M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-5.0422.1486.8826.71Price / SalesN/A458.33605.32131.81Price / CashN/A47.8637.9061.31Price / BookN/A9.9312.556.55Net IncomeN/A-$52.80M$3.31B$277.50M7 Day Performance9.17%5.22%4.28%2.42%1 Month Performance24.76%10.61%6.90%8.63%1 Year Performance13.91%25.03%70.54%31.60% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma2.5765 of 5 stars$1.31-0.8%$16.00+1,121.4%+12.9%$48.56MN/A-5.04N/AShort Interest ↓Gap UpMISTMilestone Pharmaceuticals1.8186 of 5 stars$1.93-4.0%$4.50+133.2%+40.7%$170.84M$1M-2.3030IPHAInnate Pharma2.6867 of 5 stars$1.82-0.8%$6.50+258.1%-5.0%$168.70M$21.77M0.00220ACTUActuate Therapeutics1.5007 of 5 stars$6.88-3.0%$20.33+195.5%-6.4%$164.79MN/A0.0010ENTAEnanta Pharmaceuticals4.0644 of 5 stars$7.17-6.9%$20.20+181.7%-9.5%$164.61M$67.64M-1.66160News CoverageAnalyst ForecastAnalyst RevisionTVGNTevogen Bio2.1742 of 5 stars$0.80-4.2%$10.00+1,150.0%+141.5%$164.33MN/A-4.213Gap DownNVCTNuvectis Pharma3.2775 of 5 stars$6.00-6.7%$15.33+155.6%-1.5%$163.69MN/A-5.138GLSIGreenwich LifeSciences1.1269 of 5 stars$10.98-6.9%$42.00+282.5%-20.6%$160.84MN/A-8.073News CoverageNLTXNeoleukin TherapeuticsN/A$16.98-1.3%N/A-54.0%$159.58MN/A-5.4690High Trading VolumeBTMDbiote2.341 of 5 stars$3.09-4.0%$6.00+94.2%-41.9%$159.19M$199.07M3.43194CLYMClimb Bio3.9742 of 5 stars$2.25-3.0%$9.00+300.0%N/A$157.21MN/A-3.219Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies Milestone Pharmaceuticals Competitors Innate Pharma Competitors Actuate Therapeutics Competitors Enanta Pharmaceuticals Competitors Tevogen Bio Competitors Nuvectis Pharma Competitors Greenwich LifeSciences Competitors Neoleukin Therapeutics Competitors biote Competitors Climb Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
